IMNM Immunome Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472012 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-63.3%
TTM net income YoY-9.5%
TTM EPS YoY20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,947.9%
Net margin-5,593.8%
FCF margin-5,118.9%
EBITDA margin-5,886.7%
Returns
ROE-50.1%
ROA-46.7%
ROIC (approx.)-679.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.0%
Debt / equity0.00x
Current ratio21.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue224.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.94M | $9.04M | $14.02M | — | — |
| R&D expense | $177.29M | $129.54M | $23.09M | $23.27M | $14.11M |
| SG&A expense | $43.77M | $32.95M | $19.66M | $13.63M | $11.09M |
| Operating income | -$224.11M | -$305.80M | -$109.53M | -$36.90M | -$25.20M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M |
| EBITDA | -$221.65M | -$304.23M | -$109.07M | -$36.48M | -$24.45M |
| EPS (basic) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 |
| EPS (diluted) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 |
| Weighted avg. shares (diluted) | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M |
| Banking | |||||
| Net interest income | $11.72M | $12.84M | $2.72M | $5,000 | -$10,000 |
| Balance sheet | |||||
| Cash & equivalents | $653.48M | $143.45M | $98.78M | $20.42M | $49.33M |
| Short-term investments | $0 | $73.95M | $39.46M | — | — |
| Current assets | $660.78M | $221.34M | $144.70M | $22.65M | $56.64M |
| PP&E, net | $14.64M | $10.11M | $2.07M | $681,000 | $855,000 |
| Total assets | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M |
| Current liabilities | $44.99M | $54.31M | $21.83M | $7.33M | $9.73M |
| Total liabilities | $48.84M | $59.08M | $28.66M | $7.39M | $9.74M |
| Shareholders' equity | $634.34M | $181.16M | $119.88M | $16.65M | $48.19M |
| Shares outstanding | 113.13M | 64.46M | 43.25M | 12.13M | 12.11M |
| Cash flow statement | |||||
| Operating cash flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M |
| Capital expenditure | $9.69M | $7.17M | $831,000 | $248,000 | $79,000 |
| Free cash flow | -$200.60M | -$117.97M | -$8.40M | -$28.94M | -$18.30M |
| Investing cash flow | $60.80M | -$85.06M | -$30.48M | -$248,000 | -$79,000 |
| Financing cash flow | $640.36M | $240.53M | $116.41M | $32,000 | $27.77M |
| Depreciation & amortization | $2.47M | $1.57M | $457,000 | $422,000 | $755,000 |
| Stock-based compensation | $25.69M | $15.75M | $6.22M | $5.33M | $3.45M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.